ASCOconnection.org is a forum for the exchange of views on topical issues in the field of oncology. The views expressed in the blogs, comments, and forums belong to the authors. They do not necessarily reflect the views or positions of the American Society of Clinical Oncology. Please read the Commenting Guidelines.
The good kind of problem is having too many choices; the bad kind of problem is having too few choices. Today, I am writing about the ultimate in the good kind of problems: Being an exceptional responder to cancer treatment. I am even trying to enroll in the NCI Exceptional Responders Initiative.
This year’s Community Research Forum Annual Meeting is right around the corner. As Chair of the CRF Council, I am very excited about the Meeting and would like to invite you to participate in this unique opportunity.
Looking back on the 1976 Bonadonna study using CMF chemotherapy in women with breast cancer and positive axillary nodes, I consider what went wrong in the search for similarly effective treatment of prostate cancer.
Clinical investigation forms the backbone and the history of medical oncology. Cancer clinical trials provide the evidence we need to demonstrate safety and efficacy before Food and Drug Administration (FDA) approval and evidence for our clinical treatment guidelines.
However, it seems to be more...
As physicians who take care of patients with cancer, all of us worldwide have the same goals of cancer prevention, early detection and screening, improvement in the quality of cancer care, and accelerating research and new therapies. The question is, how can we accomplish these goals in a world...
Please join the Conquer Cancer Foundation as we extend the momentum of The Campaign to Conquer Cancer. As much as we need your donations to raise $150 million, we need your leadership and your voice even more.
At a reception well attended by many prominent thoracic oncologists this week, after the last lung cancer sessions of this year’s ASCO Annual Meeting had ended, the atmosphere was jubilant. Some were relieved that their presentations had gone well and that they could finally relax. Most were glad...
As someone who is interested in prostate cancer almost exclusively in my practice, listening to Dr. Nicholas James present the data from the STAMPEDE trial was of high interest.
A few months ago, I became aware of the ongoing measles outbreak that has been traced back to visits to Disneyland in Anaheim, CA, which began in December 2014. I remember reading the news reports, including the defense of those who did not believe that vaccines are safe, and witnessed the pleas...
For the past month or so, one patient after another has come in with the question, “So, what do you think about 4-MU?” or “Did you hear about poliovirus killing cancer?” Actually, I have heard next to nothing about either, but of course I was intrigued as to where my patients get their information.
It has long been held that testosterone is the root of all evil—probably true for most wars, and possibly true for the development of prostate cancer....
For years now, we have had a raging debate in the renal cell carcinoma (RCC) community regarding the use of adjuvant therapy. In a patient with no evidence of metastatic disease following surgery, the standard...
I happened to be standing in her office when Tina, our research nurse, received an email from one of our patients. This patient had recurrent ovarian cancer and was on her third-line of treatment. She was seen at our center for clinical trials, and Tina and I had spent some time discussing one...
Blogs
ASCOconnection.org is a forum for the exchange of views on topical issues in the field of oncology. The views expressed in the blogs, comments, and forums belong to the authors. They do not necessarily reflect the views or positions of the American Society of Clinical Oncology. Please read the Commenting Guidelines.
No Results.
Pages
Advertisement